摘要
目的观察慢性肝病患者血清可溶性白介素－６受体（Ｓｏｌｕｂｌｅ ｉｎｔｅｒｌｅｕｋｉｎ－６ ｒｅｃｅｐｔｏｒ，ｓｉＬ－６Ｒ）和可溶性ＩＬ－６受体β链（ｓｇｐ１３０）的变化。方法应用酶联免疫吸咐法检测慢性肝炎患者４０例、肝炎后肝硬化患者１５例和３５例健康对照者血清中ｓＩＬ－６Ｒ和ｓｇｐ１３０水平。结果慢性肝炎患者血清ｓＩＬ－６Ｒ和ｓｇｐ１３０含量（μｇ／Ｌ）分别为２２４．２７和４８９．３５均显著高于健康对照组（ｕｇ／Ｌ）分别为１７４．８１和２７３．６４，其中肝炎后肝硬化组患者上述二参数高于慢性肝炎各组；慢性肝炎组中的上述二参数显示为重度＞中度＞轻度，各组间差异有显著意义；慢性肝病组血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平之间呈正相关（ｒ＝ ０．４８１， Ｐ＜ ００５）， ｓＩＬ－６Ｒ、 ｓｇｐ１３０水平与血清总胆红素水平间亦呈正相关（ｒ分别为０．４１７和０４２８， Ｐ值均＜ ０．０１），与ＡＬＴ之间无明显相关性（ｒ分别为０．１７３和０１８２， Ｐ值均＞０．０５）。结论血清ｓＩＬ－６Ｒ和ｓｇｐ １３０与慢性肝病的病情演变有关，对其预后有一定指导意义。
Objective To observe the variation of soluble interleukin-6 receptor(sIL-6R) and soluble interleukin- 6 receptor β strands(sgpl30) in patients with chronic hepatopath. Methods We examined sIL-6R and sgpl30 level in 40 patients with chronic hepatitis(CH), 15 with cirrhosis following hepatitis, and 35 normal controls(NC) in serum by enzyme linked immunosorbent assay (ELISA) method. Results The content of sIL-6R and sgpl30 in serum was higher in CH group(224.27 ug/L and 489.35 ug/L, respectively) than NC group(174.81 ug/L and 273.64 ug/L respectively). The two parameters above in patients with hepatocirrhosis were higher than those in patients with chronic hepatitis, and the content in order of quantity was severe > moderate > slight. There was significant difference among the three groups(P < 0.05, P < 0.01), and positive correlation between sIL-6R and sgp 130 level(r = 0.481, P < 0.05), between sIL-6R, sgpl30 level and total bilirubin level(r = 0.417, r = 0.428, P < 0.01). While sIL-6R, sgpl30 was no significant correlation to ALT(r = 0.173, r = 0.182, P > 0.05). Conclusion sIL-6R and sgp130 in serum are associated with the development of chronic hepatopath, and therefore can guide the assessment of prognosis.
出处
《中华肝脏病杂志》
CAS
CSCD
2000年第2期87-88,共2页
Chinese Journal of Hepatology
关键词
病毒性肝炎
肝硬化
SIL-6R
SGP130
血清诊断
Chronic viral hepatitis
Liver cirrhosis
Soluble interleukin-6 receptor
Soluble interieukin-6 receptor β strands
